Top

Published in:

01-07-2014 | Original Article

Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls

Authors: Noriko Ando-Tanabe, Yumi Iwamitsu, Masaru Kuranami, Shigemi Okazaki, Hiroe Yasuda, Yuki Nakatani, Kenji Yamamoto, Masahiko Watanabe, Hitoshi Miyaoka

Published in: Breast Cancer | Issue 4/2014

Abstract

Background

The aim of this study was to evaluate the impact of chemotherapy and psychological distress on cognitive function in patients with breast cancer receiving chemotherapy compared to healthy controls.

Methods

Eighteen women with non-metastatic breast cancer who have been exposed to chemotherapy were evaluated with a battery of neuropsychological and psychological tests before (time 1) and 1 month after chemotherapy (time 2). Twenty healthy women were assessed at matched intervals.

Results

The relationship between cognitive change and mood change from time 1 to time 2 was compared between breast cancer patients and healthy controls. Independent t tests revealed no differences in change scores for each neuropsychological test and psychological questionnaire between the chemotherapy and control groups. However, in the chemotherapy group, change scores for verbal memory test and executive function test were significantly and negatively correlated with change score for Hospital Anxiety and Depression Scale (HADS)-D (r ≤ −0.498, p < 0.05). Furthermore, change scores for the verbal memory test and processing function test were also significantly and negatively correlated with change score for HADS-A (r ≤ −0.503, p < 0.05). The multiple regression model for the processing function test accounted for a significant amount of variance (model adjusted R ² = 0.157, p < 0.05), where the standard partial regression coefficient for HADS-A change score was statistically significant (β = −0.441, p < 0.01), whereas the standard partial regression coefficients for the group and for the HADS-D change score were −0.297 (p = 0.071) and 0.026 (p = 0.868), respectively.

Conclusions

Higher psychological distress was associated with poor cognitive function in patients receiving chemotherapy in this study.

Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20(2):485–93.PubMedCrossRef

Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18(14):2695–701.PubMed

Eberhardt B, Dilger S, Musial F, Wedding U, Weiss T, Miltner WH. Short-term monitoring of cognitive functions before and during the first course of treatment. J Cancer Res Clin Oncol. 2006;132(4):234–40. doi:10.1007/s00432-005-0070-8.PubMedCrossRef

Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009;115(8):1776–83. doi:10.1002/cncr.24192.PubMedCentralPubMedCrossRef

Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol. 2001;51(2):159–65.PubMedCrossRef

Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85(3):640–50. doi:10.1002/(SICI)1097-0142(19990201)85:3<640:AID-CNCR14>3.0.CO;2-G.PubMedCrossRef

van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst. 1998; 90(3): 210–8.

Yamada TH, Denburg NL, Beglinger LJ, Schultz SK. Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci. 2010;22(1):48–54. doi:10.1176/appi.neuropsych.22.1.48.PubMedCentralPubMedCrossRef

Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104(11):2499–507. doi:10.1002/cncr.21482.PubMedCentralPubMedCrossRef

10.

Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, et al. Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol. 2006;17(3):415–23. doi:10.1093/annonc/mdj108.PubMedCrossRef

11.

Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology. 2006;15(5):422–30. doi:10.1002/pon.964.PubMedCrossRef

12.

Jansen CE, Dodd MJ, Miaskowski CA, Dowling GA, Kramer J. Preliminary results of a longitudinal study of changes in cognitive function in breast cancer patients undergoing chemotherapy with doxorubicin and cyclophosphamide. Psychooncology. 2008;17(12):1189–95. doi:10.1002/pon.1342.PubMedCrossRef

13.

Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116(1):113–23. doi:10.1007/s10549-008-0114-2.PubMedCrossRef

14.

Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology. 2008;17(2):122–30. doi:10.1002/pon.1210.PubMedCrossRef

15.

Debess J, Riis JO, Engebjerg MC, Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat. 2010;121(1):91–100. doi:10.1007/s10549-010-0756-8.PubMedCrossRef

16.

Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer. 2007;109(9):1905–13. doi:10.1002/cncr.22610.PubMedCrossRef

17.

Mehlsen M, Pedersen AD, Jensen AB, Zachariae R. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology. 2009;18(3):248–57. doi:10.1002/pon.1398.PubMedCrossRef

18.

Tager FA, McKinley PS, Schnabel FR, El-Tamer M, Cheung YK, Fang Y, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2010;123(1):25–34. doi:10.1007/s10549-009-0606-8.PubMedCrossRef

19.

McCaffrey RJ, Duff K, Westervelt HJ. Practitioner’s guide to evaluating change with intellectual assessment instruments. NY: Springer; 2000.

20.

McCaffrey RJ, Duff K, Westervelt HJ. Practitioner’s guide to evaluating change with neuropsychological assessment instruments. NY: Springer; 2000.

21.

Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292–9. doi:10.1002/cncr.20272.PubMedCrossRef

22.

Ahles TA, Saykin AJ, McDonald BC, Furstenberg CT, Cole BF, Hanscom BS, et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat. 2008;110(1):143–52. doi:10.1007/s10549-007-9686-5.PubMedCentralPubMedCrossRef

23.

Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004;101(3):466–75. doi:10.1002/cncr.20393.PubMedCrossRef

24.

Cimprich B, So H, Ronis DL, Trask C. Pre-treatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psychooncology. 2005;14(1):70–8. doi:10.1002/pon.821.PubMedCrossRef

25.

Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94(6):828–34. doi:10.1038/sj.bjc.6603029.PubMedCentralPubMedCrossRef

26.

Buckelew SP, Hannay HJ. Relationships among anxiety, defensiveness, sex, task difficulty, and performance on various neuropsychological tasks. Percept Mot Skills. 1986;63(2 Pt 2):711–8.PubMedCrossRef

27.

Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116(14):3348–56. doi:10.1002/cncr.25098.PubMedCrossRef

28.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.PubMedCrossRef

29.

Zigmond AS, Snaith RP, Kitamura T. Hospital Anxiety and Depression Scale (HAD scale). Archives of psychiatric diagnostics and clinical evaluation. Seishinka Shindan Gaku. 1993;4(3):371–2.

30.

Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.PubMedCrossRef

31.

Cohen J. A power primer. Psychol Bull. 1992;112(1):155–9.PubMedCrossRef

32.

Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, et al. Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol. 2010;76(2):133–41. doi:10.1016/j.critrevonc.2009.11.001.PubMedCrossRef

33.

Reid-Arndt SA, Yee A, Perry MC, Hsieh C. Cognitive and psychological factors associated with early posttreatment functional outcomes in breast cancer survivors. J Psychosoc Oncol. 2009;27(4):415–34. doi:10.1080/07347330903183117.PubMedCentralPubMedCrossRef

34.

Golden CJ, Espe-Pfeifer P, Wachsler-Felder J. Neuropsychological interpretations of objective psychological tests. New York: Kluwer Academic/Plenum; 2000.

35.

Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G. Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc. 2009;15(6):951–62. doi:10.1017/S1355617709990567.PubMedCrossRef

36.

Dotson VM, Resnick SM, Zonderman AB. Differential association of concurrent, baseline, and average depressive symptoms with cognitive decline in older adults. Am J Geriatr Psychiatry. 2008;16(4):318–30. doi:10.1097/JGP.0b013e3181662a9c.PubMedCentralPubMedCrossRef

37.

Singh-Manoux A, Akbaraly TN, Marmot M, Melchior M, Ankri J, Sabia S, et al. Persistent depressive symptoms and cognitive function in late midlife: the Whitehall II study. J Clin Psychiatry. 2010;71(10):1379–85. doi:10.4088/JCP.09m05349gry.PubMedCentralPubMedCrossRef

38.

Biringer E, Mykletun A, Dahl AA, Smith AD, Engedal K, Nygaard HA, et al. The association between depression, anxiety, and cognitive function in the elderly general population—the Hordaland Health Study. Int J Geriatr Psychiatry. 2005;20(10):989–97. doi:10.1002/gps.1390.PubMedCrossRef

39.

Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28(29):4434–40. doi:10.1200/JCO.2009.27.0827.PubMedCentralPubMedCrossRef

40.

Biglia N, Moggio G, Peano E, Sgandurra P, Ponzone R, Nappi RE, et al. Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med. 2010;7(5):1891–900. doi:10.1111/j.1743-6109.2010.01725.x.PubMedCrossRef

41.

Calvio L, Peugeot M, Bruns GL, Todd BL, Feuerstein M. Measures of cognitive function and work in occupationally active breast cancer survivors. J Occup Environ Med. 2010;52(2):219–27. doi:10.1097/JOM.0b013e3181d0bef7.PubMedCrossRef

42.

Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs. 2007;11(1):6–15. doi:10.1016/j.ejon.2006.02.005.PubMedCrossRef

43.

Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol. 2010;28(8):1294–300. doi:10.1200/JCO.2008.21.3553.PubMedCrossRef

44.

Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer. 2008;113(9):2431–9. doi:10.1002/cncr.23853.PubMedCrossRef

45.

Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv. 2009;3(4):223–32. doi:10.1007/s11764-009-0098-x.PubMedCentralPubMedCrossRef

46.

Cappiello M, Cunningham RS, Knobf MT, Erdos D. Breast cancer survivors: information and support after treatment. Clin Nurs Res 2007; 16(4): 278–93 (discussion 94–301). doi:10.1177/1054773807306553.

47.

Munir F, Burrows J, Yarker J, Kalawsky K, Bains M. Women’s perceptions of chemotherapy-induced cognitive side affects on work ability: a focus group study. J Clin Nurs. 2010;19(9–10):1362–70. doi:10.1111/j.1365-2702.2009.03006.x.PubMedCrossRef

Title: Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls
Authors: Noriko Ando-Tanabe
Yumi Iwamitsu
Masaru Kuranami
Shigemi Okazaki
Hiroe Yasuda
Yuki Nakatani
Kenji Yamamoto
Masahiko Watanabe
Hitoshi Miyaoka
Publication date: 01-07-2014
Publisher: Springer Japan
Published in: Breast Cancer / Issue 4/2014
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-012-0405-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

Association of ErbB1–4 expression in invasive breast cancer with clinicopathological characteristics and prognosis

Promotion of quality-controlled mammography alone as a screening modality in Japan

Comparison of conventional and automated breast volume ultrasound in the description and characterization of solid breast masses based on BI-RADS features

Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response

A case of metaplastic breast cancer that showed a good response to platinum-based preoperative chemotherapy

Comparison of hypofractionated and conventionally fractionated whole-breast irradiation for early breast cancer patients: a single-institute study of 1,098 patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer